Virtu Financial LLC Acquires 119,407 Shares of Pfizer Inc. (NYSE:PFE)

Virtu Financial LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 230.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 171,190 shares of the biopharmaceutical company’s stock after purchasing an additional 119,407 shares during the period. Virtu Financial LLC’s holdings in Pfizer were worth $4,542,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its holdings in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI grew its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 159,984 shares during the last quarter. NFJ Investment Group LLC grew its holdings in Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock valued at $11,129,000 after purchasing an additional 43,719 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in Pfizer by 25.9% during the 3rd quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company’s stock valued at $23,283,000 after purchasing an additional 165,611 shares during the last quarter. Finally, Copley Financial Group Inc. bought a new position in Pfizer during the 3rd quarter valued at about $577,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday. Finally, Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Up 0.1 %

NYSE:PFE opened at $26.20 on Friday. The firm has a market capitalization of $148.61 billion, a P/E ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company’s fifty day moving average price is $26.17 and its 200-day moving average price is $27.05. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.